Adocia SA · EURONEXT:ADOC

Adocia SA — Investor Presentation (September 2018)

36 slides from Adocia SA's investor presentation, September 2018

  1. Slide 1: Corporate Presentation September 2018

    Slide 1: Corporate Presentation September 2018

    ADOCIA INNOVATIVE MEDICINE FOR EVERYONE, EVERYWHERE Corporate Presentation September 2018

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    INTRODUCTION Disclaimer This corporate presentation (the “Presentation”) has been prepared by ADOCIA (the “Company”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompa

  3. Slide 3: ADOCIA in summary

    Slide 3: ADOCIA in summary

    ADOCIA ADOCIA in summary Business model delivers cost-effective innovation based on already-approved 1 proteins, enhanced with BioChaperone® Key clinical diabetes assets including ultra-rapid insulin BC Lispro, modern premix 2 BC Combo, BC Pramlintide Insulin and ready-to-use BC Glucagon 3 $50M upfr

  4. Slide 4: Adocia's management and team

    Slide 4: Adocia's management and team

    ADOCIA Adocia’s management and team Gérard Soula Olivier Soula Valérie Rémi Soula Steve Daly PhD, MBA PhD, MBA Danaguezian PhD, MBA President & CEO Deputy General Manager, Chief Financial Officer Director of BD & Legal US General Manager Co-founder Director of R&D Co-founder Co-founder  Focused on

  5. Slide 5: BioChaperone Technology

    Slide 5: BioChaperone Technology

    BIOCHAPERONE® TECHNOLOGY 5 September 2018

  6. Slide 6: BioChaperone unlocks the potential of proteins and peptides

    Slide 6: BioChaperone unlocks the potential of proteins and peptides

    ADOCIA BioChaperone® unlocks the potential of proteins and peptides and their combinations in a cost-effective way BioChaperone® Proteins and peptides (insulin, GLP-1 RA, pramlintide, (library of molecules) glucagon, teduglutide…) [BioChaperone® Protein] Complex  Improved solubility Improved stabi

  7. Slide 7: BioChaperone-enabled innovation in diabetes and beyond

    Slide 7: BioChaperone-enabled innovation in diabetes and beyond

    ADOCIA BioChaperone-enabled innovation in diabetes and beyond Diabetes clinical pipeline Preclinical pipeline In vitro PC Phase I/II Phase III In vitro PC Phase I/II BC Lispro U100 Diabetes THDB BC Lispro U200 BC Gla GLP-1 THDB BC Combo Other indications (BC Gla Lis) BC Gluc GLP-1 Obesity HinsBet U1

  8. Slide 8: Important Year-to-Date Developments

    Slide 8: Important Year-to-Date Developments

    KEY DEVELOPMENTS Important Year-to-Date Developments BUSINESS PIPELINE  Strategic alliance with Tonghua Dongbao  BC Pramlintide Insulin:  April 2018 – 2 Licensing agreements for BC Lispro &  Promising FIH results showing -97% reduction BC Combo in China & other Asian and Middle-East in glycemic

  9. Slide 9: Adocia Lead Insulin Programs

    Slide 9: Adocia Lead Insulin Programs

    ADOCIA LEAD INSULIN PROGRAMS BIOCHAPERONE® LISPRO & BIOCHAPERONE® COMBO 9 September 2018

  10. Slide 10: People with diabetes require simpler, more physiologic treatments

    Slide 10: People with diabetes require simpler, more physiologic treatments

    MARKET People with diabetes require simpler, more physiologic treatments 425M1 26M 2  Despite 100 years of medical treatment, long-term consequences of diabetes remain a major issue people with on insulin diabetes in 2017  There is a need to address the underlying complexity of diabetes  With mor

  11. Slide 11: BioChaperone Insulin formulations fit the medical need for innovation

    Slide 11: BioChaperone Insulin formulations fit the medical need for innovation

    MARKET BioChaperone® Insulin formulations fit the medical need for innovation in the prandial space  BioChaperone® Insulins deliver disruptive innovation for prandial insulin therapy:  Best-in-class injectable products for prandial glycemic control  Potential to be priced competitively (based on

  12. Slide 12: Adocia and Tonghua Dongbao entered strategic alliance

    Slide 12: Adocia and Tonghua Dongbao entered strategic alliance

    TONGHUA DONGBAO Adocia and Tonghua Dongbao entered strategic alliance to develop best-in-class insulins  Adocia and Tonghua Dongbao (THDB) strategic alliance:  Licensing agreements for BioChaperone (BC) Lispro & BC Combo  Supply agreements for insulin glargine and insulin lispro  THDB is the loc

  13. Slide 13: Strategic licensing deals with THDB for BC Lispro & BC Combo

    Slide 13: Strategic licensing deals with THDB for BC Lispro & BC Combo

    LICENSE Strategic licensing deals with THDB for BC Lispro & BC Combo in Chinese market >100M1  Large and underserved Chinese insulin market features multiple drivers for growth People with diabetes in 65%2  Rapidly growing (CAGR 12%)2, with the number of treated patients set to double in the 30M 3

  14. Slide 14: Strategic supply agreements with THDB open global opportunities

    Slide 14: Strategic supply agreements with THDB open global opportunities

    SUPPLY Strategic supply agreements with THDB open global opportunities for Adocia  With access to stable, high-quality insulin lispro and insulin glargine supply, Adocia now gains full control over BC Lispro and BC Combo development, notably in US, EU and Japan:  Partnering opportunities are multi

  15. Slide 15: BC Lispro: Ultra-rapid insulin with best-in-class potential

    Slide 15: BC Lispro: Ultra-rapid insulin with best-in-class potential

    Licensed to THDB in China BC LISPRO Ultra-rapid insulin with best-in-class potential  BioChaperone® Lispro could be a differentiated competitor to Fiasp® (1st approved ultra-rapid insulin, Novo Nordisk). $7B Ready for  Consistently faster-on and faster-off metabolic effect vs. Prandial insulin Hum

  16. Slide 16: Ultra-rapid insulin is key to close the loop

    Slide 16: Ultra-rapid insulin is key to close the loop

    BC LISPRO Ultra-rapid insulin with a fast-on and fast-off profile is key element to « close the loop » Smart Adocia intends to initiate its CGM Pumps & pens first Phase 3 trial in the insulin pump setting in 2019 16 September 2018

  17. Slide 17: BC Combo: safer, more efficient alternative to premix insulin

    Slide 17: BC Combo: safer, more efficient alternative to premix insulin

    Licensed BC COMBO A safer and more efficient alternative to premix to THDB in China insulin for the treatment of type 2 diabetes $5B  Premix products are easier to use than basal-bolus regimens but present inferior prandial coverage and a higher risk of hypoglycemia Premix insulin market (2016)1 

  18. Slide 18: Multihormonal Treatments for Diabetes

    Slide 18: Multihormonal Treatments for Diabetes

    MULTIHORMONAL TREATMENTS FOR DIABETES NEXT GENERATION OF CARE FOR BETTER OUTCOMES 18 September 2018

  19. Slide 19: Multi-hormonal approaches to improve diabetes and obesity management

    Slide 19: Multi-hormonal approaches to improve diabetes and obesity management

    RATIONALE Innovative multi-hormonal approaches aim to improve diabetes and obesity management Insulin In combination BC Glargine GLP-1 (T2D) BC Pramlintide rhIns (T1D & T2D) GLP-1 Amylin In combination In a dual-chamber pump BC Glucagon GLP-1 BC Glucagon with Insulin (T1D) (Obesity) Glucagon As a se

  20. Slide 20: Time-sensitive hormonal pattern maintains normo-glycemia

    Slide 20: Time-sensitive hormonal pattern maintains normo-glycemia

    DIABETES In non-diabetic people, a time-sensitive hormonal pattern maintains normo-glycemia Schematic representation of hormonal pattern1 Insulin Without diabetes With Type 1 diabetes (T1D) Level of secretion Amylin (relative scale) Glucagon GLP-1 GLP-1 Glucagon Insulin Amylin 0 1 2 3 4 5 6 0 1 2 3

  21. Slide 21: BC Pram Insulin: next generation prandial treatment in T1D

    Slide 21: BC Pram Insulin: next generation prandial treatment in T1D

    BC PRAM Next generation of prandial treatment to improve long- INSULIN term outcomes in T1D 79%2 Of diabetics live with severe 65%3 complications  BioChaperone® Pramlintide Insulin aims to deliver an of US adults with exceptionally tight prandial control, based on clinical use T1D are overweight of

  22. Slide 22: Topline data from first-in-human trial of BC Pramlintide Insulin

    Slide 22: Topline data from first-in-human trial of BC Pramlintide Insulin

    BC PRAM Promising topline data from first-in-human trial of INSULIN BioChaperone® Pramlintide Insulin  In a standardized mixed meal test study in 24 people with T1D1, BioChaperone Pramlintide Insulin (injected at mealtime) showed:  97% decrease of glycemic excursion in the first 2 hours vs. Humalo

  23. Slide 23: BC Glucagon: ready-to-use aqueous formulation of human glucagon

    Slide 23: BC Glucagon: ready-to-use aqueous formulation of human glucagon

    BC GLUCAGON A ready-to-use aqueous formulation of human glucagon for acute and chronic use $400M  BioChaperone® Glucagon is a ready-to-use aqueous formulation of human glucagon supporting: Forecasted market in 20251  Rescue treatment of severe hypoglycemia in a ready-to-use autoinjector: current g

  24. Slide 24: Expanding the Portfolio

    Slide 24: Expanding the Portfolio

    EXPANDING THE PORTFOLIO LEVERAGING BIOCHAPERONE®TRACK-RECORD AND VERSATILITY TO ADDRESS NEW THERAPEUTIC TARGETS 24 September 2018

  25. Slide 25: BioChaperone improves approved or NCE proteins and peptides

    Slide 25: BioChaperone improves approved or NCE proteins and peptides

    BC PLATFORM BioChaperone® can be used to improve both approved or NCE proteins and peptides BioChaperone® /Protein complex  Leveraging Adocia core competencies in protein and peptide formulation to fit partner’s needs  More than 20 clinical trials (Phase 1-3) to date on 6 different pharmaceutical

  26. Slide 26: Expanding the use of BioChaperone platform

    Slide 26: Expanding the use of BioChaperone platform

    PIPELINE EXPANSION Expanding the use of BioChaperone® platform  BioChaperone Glucagon GLP-1 for the treatment of obesity  Obesity prevalence has tripled from 1975 to 2016 globally2, triggering the development of more aggressive treatment regimens: 36.5%1 of US adults are  Based on BC Glucagon, Ad

  27. Slide 27: Key financial elements

    Slide 27: Key financial elements

    ADOCIA Key financial elements Financial summary Shareholders’ equity (August 2018) Analysts  Listed on Euronext Paris (ADOC) Free Float Soula Family 22.1 %  Kepler Market (Arsène Guekam) 59.6%  Oddo (Pierre Corby)  6.9M shares outstanding  Louis Capital Partners (Pierre Vaurice)  Edison (Juan

  28. Slide 28: Expected News Flow

    Slide 28: Expected News Flow

    ADOCIA Expected News Flow BUSINESS PIPELINE  BC LISPRO  BC LISPRO  Looking to partner in US/EU/Japan  Phase 3 start planned in 2019  BC COMBO  BC PRAMLINTIDE INSULIN  Looking to partner in US/EU/Japan & other premix markets  HinsBet (BC rHI)  Second Phase 1/2 trial planned in Q1 19  Lookin

  29. Slide 29: Thank you for your kind interest

    Slide 29: Thank you for your kind interest

    THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com 29 September 2018

  30. Slide 30: Appendix

    Slide 30: Appendix

    APPENDIX 30 September 2018 @ADOCIA f-

  31. Slide 31: Medical Advisory Board

    Slide 31: Medical Advisory Board

    ADOCIA Adocia is supported by a top-tier Medical Advisory Board  Dr. Jay Skyler, MD, Chairman, University of Miami (US)  Dr. Vanita Aroda, MD, MedStar Health Research Institute (US)  Dr. Bruce Bode, MD, Emory University (US)  Dr. John Buse, MD, PhD, University of North Carolina (US)  Dr. Eda Ce

  32. Slide 32: HinsBet: affordable prandial insulin

    Slide 32: HinsBet: affordable prandial insulin

    HINSBET Affordable prandial insulin for price-sensitive populations $1B Human prandial  HinsBet is a formulation of human insulin designed to act as rapidly as insulin market an insulin analog (2016)1  Human insulin is the most common prandial insulin choice in low- income countries, but diffuses

  33. Slide 33: BC Lispro results vs Humalog U100 in T1DM

    Slide 33: BC Lispro results vs Humalog U100 in T1DM

    BC LISPRO Results summary compared to Humalog U100 in T1DM subjects 294-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Biochaperone Lispro: Shorter TMAX, Higher CMAX  BioChaperone Lispro in comparison with and Similar Exposure Greater Earlier Exposure: Faster In Humalo

  34. Slide 34: BC Combo results vs Lispro Mix 75/25 in T1DM

    Slide 34: BC Combo results vs Lispro Mix 75/25 in T1DM

    BC COMBO Results summary compared to Conventional Lispro Mix 75/25 in T1DM subjects 295-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Mean Unadjusted BG Profiles ± SEM Over 6hr After s.c. Cumulative Percentage of Subjects With BG Values < 63 mg/dL Administration of Ind

  35. Slide 35: BC Combo results vs Humalog 75/25 in T2DM

    Slide 35: BC Combo results vs Humalog 75/25 in T2DM

    BC COMBO Results summary compared to Humalog 75/25 in T2DM subjects 942-P in 12-B Clinical Therapeutics/ New Technology-Insulins, June 11, 2016, 76th ADA Scientific Sessions Smoothed GIR Profiles (0-30h) of 0.8 U/kg BioChaperone Combo, 0.8 Smoothed GIR Profiles (0-2h) of 0.8 U/kg BioChaperone U/kg H

  36. Slide 36: Thank you for your kind interest

    Slide 36: Thank you for your kind interest

    THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com 36 September 2018

Source: Internet Archive copy of adocia.com

More decks from Adocia SA

All 49 Adocia SA decks